Goserelin
Also referenced as: Zoladex
A GnRH agonist implant used for selected hormone-sensitive conditions.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Zoladex indications vary by implant, including prostate cancer and selected presentations for endometriosis, endometrial thinning or advanced breast cancer.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH agonist implant used for selected hormone-sensitive conditions.
Zoladex indications vary by implant, including prostate cancer and selected presentations for endometriosis, endometrial thinning or advanced breast cancer.
Implant presentations have different indications; suppression of sex hormones is not sexual-health enhancement.
Why It's Being Studied
- Hormone-sensitive cancers
- Endometriosis
- Sex-steroid suppression
Mechanism of Action
Initial stimulation is followed by pituitary desensitization and suppression of gonadal steroids.
Initial stimulation is followed by pituitary desensitization and suppression of gonadal steroids. Implant presentations have different indications; suppression of sex hormones is not sexual-health enhancement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Hormone-sensitive cancers
- Endometriosis
- Sex-steroid suppression
- Approved subcutaneous implant
Evidence Summary
Human evidence supports product-specific prostate-cancer, breast-cancer and selected gynecologic indications.
Higher tiers carry more weight. Filled tiers have evidence for Goserelin; tap to read it.
- Human evidence supports product-specific prostate-cancer, breast-cancer and selected gynecologic indications.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human evidence supports product-specific prostate-cancer, breast-cancer and selected gynecologic indications.
Reported Adverse Events in Research
- Tumor flare, bone loss, metabolic or cardiovascular effects and rare serious implantation injury are important.
Limitations of Current Evidence
- Implant presentations have different indications; suppression of sex hormones is not sexual-health enhancement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Goserelin | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Approved subcutaneous implant | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Goserelin — prescribing label